Improving Vaccines

Improving Vaccines

  • SPS® technologies increase the thermal stability of vaccines including live viral vectors
  • LEUKOCARE's laboratories have the capabilities to work with biosafety level 2 (BSL2) materials

Cutting-edge stability of dry and liquid formulations in human and animal health. Expertise in inactivated and live attenuated virus vaccines.

Back
SPS Formulated H1N1 Influenza A Vaccine Demonstrate Highly Efficient Vaccination even after Irradiation

SPS® technologies have been applied to non-enveloped and enveloped RNA and DNA viruses of many kinds, including live viral vectors like modified vaccinia ankara (MVA) or adenoviruses.

SPS® technologies stabilize and protect vaccines in dry and liquid formulations. This includes processes like lyophilization, spray drying and spray freeze drying as well as novel delivery systems such as microneedles including air drying and terminal sterilization, e.g. with irradiation.

LEUKOCARE's laboratories have the capabilities to work with biosafety level 2 (BSL2) materials for human and animal health and are therefore ready to work with a broad range of live viruses.

After lyophilization, the SPS stabilized and protected antigen demonstrated hemagglutination titers comparable to the original formulation.

Live viruses are difficult to handle and are often very temperature sensitive. Hence, virus titers can drop rapidly during processing and storage, especially at increased temperatures.

As demonstrated in the figure, SPS® stabilize adenoviruses during lyophilization and storage at 25°C for at least 75 days without major titer loss.

This allows for storage out of the cold chain, e.g. at room temperature.